关注
Pierre Mounkoro
Pierre Mounkoro
Ph.D Life Science and Health
在 i2bc.paris-saclay.fr 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
The antimalarial compound ELQ‐400 is an unusual inhibitor of the bc1 complex, targeting both Qo and Qi sites
Z Song, BI Iorga, P Mounkoro, N Fisher, B Meunier
FEBS letters 592 (8), 1346-1356, 2018
402018
Mitochondrial complex III Qi‐site inhibitor resistance mutations found in laboratory selected mutants and field isolates
P Mounkoro, T Michel, R Benhachemi, G Surpateanu, BI Iorga, N Fisher, ...
Pest management science, 2018
302018
Successful use of empagliflozin to treat neutropenia in two G6PC3‐deficient children: Impact of a mutation in SGLT5
C Boulanger, X Stephenne, J Diederich, P Mounkoro, N Chevalier, ...
Journal of inherited metabolic disease 45 (4), 759-768, 2022
212022
Investigating the mode of action of the redox-active antimalarial drug plasmodione using the yeast model
P Mounkoro, T Michel, S Blandin, MP Golinelli-Cohen, E Davioud-Charvet, ...
Free Radical Biology and Medicine, 2019
192019
SGLT5 is the renal transporter for 1, 5-anhydroglucitol, a major player in two rare forms of neutropenia
J Diederich, P Mounkoro, HA Tirado, N Chevalier, E Van Schaftingen, ...
Cellular and Molecular Life Sciences 80 (9), 259, 2023
102023
A role for the succinate dehydrogenase in the mode of action of the redox-active antimalarial drug, plasmodione
P Mounkoro, T Michel, MP Golinelli-Cohen, S Blandin, E Davioud-Charvet, ...
Free Radical Biology and Medicine, 2020
72020
Revisiting the mode of action of the antimalarial proguanil using the yeast model
P Mounkoro, T Michel, B Meunier
Biochemical and Biophysical Research Communications 534, 94-98, 0
6
Etude du mode d’action de composés antipaludiques qui ciblent la fonction mitochondriale, en utilisant la levure comme modèle
P Mounkoro
Université Paris-Saclay, 2020
2020
The antimalarial compound ELQ-400 is an unusual inhibitor of the bc1 complex, targeting both Qo and Qi sites.
SZH Song ZeHua, BI Iorga, P Mounkoro, N Fisher, B Meunier
2018
The antimalarial compound ELQ-400 is an unusual inhibitor of the\textitbc _\textrm1 complex, targeting both\textitQ _\textrmo and\textitQ _\textrmi sites
Z Song, BI Iorga, P Mounkoro, N Fisher, B Meunier
2018
Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children
C Boulanger, X Stephenne, J Diederich, P Mounkoro, N Chevalier, ...
系统目前无法执行此操作,请稍后再试。
文章 1–11